CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 283,580	$ 201,525
Related party receivables from collaborative arrangements	111,676	110,711
Prepaid expenses	3,953	1,367
Other current assets	1,119	70
Total current assets	400,328	313,673
Property and equipment, net	176	12
Equity and long-term investments	494,097	483,845
Capitalized fees paid to a related party, net	104,518	111,430
Right-of-use assets	3,545	97
Goodwill	5,544	0
Intangible assets	105,000	0
Deferred tax assets, net	23,274	17,327
Other assets	1,157	11
Total assets	1,137,639	926,395
Current liabilities:
Accounts payable	4,323	27
Accrued personnel-related expenses	3,871	619
Accrued interest payable	4,498	4,152
Convertible subordinated notes due 2023, net of issuance costs	96,072	0
Other accrued liabilities	17,144	1,009
Total current liabilities	125,908	5,807
Long-term debt, net of discount and issuance costs	443,178	394,653
Lease liabilities, long-term	3,091	0
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding	0	0
Common stock: $0.01 par value, 200,000 shares authorized, 69,706 and 69,566 issued and outstanding as of June 30, 2022 and December 31, 2021 respectively	697	696
Treasury stock: at cost, 32,005 shares at June 30, 2022 and December 31, 2021, respectively	(393,829)	(393,829)
Additional paid-in capital	1,183,667	1,264,024
Accumulated deficit	(402,198)	(456,148)
Total Innoviva stockholders' equity	388,337	414,743
Noncontrolling interest	177,125	111,192
Total stockholders' equity	565,462	525,935
Total liabilities and stockholders' equity	$ 1,137,639	$ 926,395